Anti-Major Depressive Disorder Raw Materials Agomelatine 138112-76-2

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Model NO.: TGY022019043003
• Product Name: Agomelatine
• Appearance: White to Powder
• Specificcation: 99%
• CAS No.: 138112-76-2
• Grade: Pharmaceuticals Grade
• Shelf Life: 2 Years
• Storage: Cool Dry Place
• Shipping Time: Within 3-7 Working Days
• Transport Package: Foil Bag, Box, Drum
• Specification: 99% min
• Trademark: TGY
• Origin: China
• HS Code: 3001200010
• Production Capacity: 1500kg/Month

Product Description

_{Product Name:AGOMELATINE}

_{Synonyms:AGOMELATINE;n-(2-(7-methoxy-1-naphthalenyl)ethyl)-acetamid;n-(2-(7-methoxy-1-naphthalenyl)ethyl)acetamide;n-(2-(7-methoxynaphth-1-yl)ethyl)acetamide;S20098,N-[2-(7-Methoxynaphth-1-yl)ethyl]acetamide;S 20098;AGOMELATIN;Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)-}

_{CAS:138112-76-2}

_MF:C15H17NO2

_MW:243.30098

_{Product Categories:Aromatics Compounds;Aromatics;Neurochemicals;APIS;API;Agomelatine;Valdoxan, Melitor, Thymanax}

_{mp :107-109°C}

_{storage temp. :-20°C Freezer}

_{Chemical Properties:White powder}

_{Usage:Agomelatine is an antidepressant drug. It is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. Activation of 5-HT2C receptors by serotonin inhibits dopamine and norepinephrine release.} 

_{Agomelatine is indicated for the treatment of major depressive episodes in adults.Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies.Two were considered "failed" trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies.The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study}.